1
Donald G Wallace, Thomas L Smestad, John M McPherson, Karl A Piez, Saeid Seyedin, Rosa Armstrong: Methods of bone repair using collagen. Collagen Corporation, Ciotti & Murashige Irell & Manella, December 6, 1988: US04789663 (186 worldwide citation)

A method of repairing bone defects by use of suspensions containing purified atelopeptide, reconstituted, fibrillar skin collagen or bone collagen powder or mixtures thereof is disclosed. The suspensions provide matrices for conductive growth of bone into the defect. The skin collagen may also be ly ...


2
George H Chu, Yasushi Ogawa, John M McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin: Collagen wound healing matrices and process for their production. Collagen Corporation, Irell & Manella, June 18, 1991: US05024841 (124 worldwide citation)

Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 t ...


3
John M McPherson, Peter C Yaeger, Marie E Brown, James G Hanlon, Francois Binette: Chondrocyte media formulations and culture procedures. Genzyme Corporation, November 21, 2000: US06150163 (83 worldwide citation)

One object of the present invention is based upon the development and use of a serum-free defined cell culture medium comprising a supplement mixture, a component mixture, a vitamin mixture, an inorganic salt mixture and amino acid mixture that avoids the problems inherent in the use of serum. In pa ...


4
George H Chu, Yasushi Ogawa, John M McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin: Processes for producing collagen matrixes and methods of using same. Collagen Corporation, Morrison & Foerster, May 5, 1992: US05110604 (69 worldwide citation)

Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 t ...


5
John S Sundsmo, George A Ksander, John M McPherson: Wound-healing composition. Collagen Corporation, Ciotti & Murashige Irell & Manella, July 26, 1988: US04760131 (65 worldwide citation)

A soft tissue wound healing composition comprising an aqueous mixture of fibrillar collagen, heparin, and undegranulated platelets or platelet releasate. The composition is applied topically to the wound site in conjunction with means to keep it at the site and hydrated or in the form of an occlusiv ...


6
George H Chu, Yasushi Ogawa, John M McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin: Collagen wound healing matrices and process for their production. Collagen Corporation, Morrison & Foerster, June 15, 1993: US05219576 (62 worldwide citation)

Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 t ...


7
John M McPherson, Danile R Twardzik, George J Todaro, Karl A Piez, Jane E Ranchalis: Method of inhibiting tumor growth sensitive to CIF-.beta.treatment. Collagen Corporation, Ciotti & Murashige Irell & Manella, March 28, 1989: US04816442 (11 worldwide citation)

Polypeptides called cartilage-inducing factors (CIFs) that are found in bone and have heretofore been identified as having in vitro cartilage-inducing activity. TGF-.beta. activity, and anti-inflammatory activity have now been found to possess potent oncostatic activity. The CIFs showed oncostatic a ...


8
John M McPherson, Tim Edmunds, Qun Zhou: Antibody-based therapeutics with enhanced ADCC activity. Genzyme Corporation, Finnegan Henderson Farabow Garrett & Dunner, April 20, 2010: US07700321 (5 worldwide citation)

Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for tar ...


9
John M McPherson, Tim Edmunds, Qun Zhou: Antibody-based therapeutics with enhanced ADCC activity. Genzyme Corporation, Finnegan Henderson Farabow Garrett & Dunner, December 6, 2011: US08071336

Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for tar ...


10
John M McPherson, Tim Edmunds, Qun Zhou: Antibody-based therapeutics with enhanced adcc activity. Finnegan Henderson Farabow Garrett & Dunner, April 26, 2007: US20070092521-A1

Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for tar ...